Christy M. Gliniak

Christy M. Gliniak

Auto-generated profile, based on publicly available information

Christy M. Gliniak

Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
NJNolwenn Joffin
Nolwenn Joffin
CGChristy M. Gliniak
Christy M. Gliniak
JFJan-Bernd Funcke
Jan-Bernd Funcke
VPVivian A. Paschoal
Vivian A. Paschoal
CCClair Crewe
Clair Crewe
PSPhilipp E Scherer
Philipp E Scherer

24 January 2022 in eLife
Verified
Journal Article
Open access
RSRebecca C Schugar
Rebecca C Schugar
CGChristy M Gliniak
Christy M Gliniak
LOLucas Osborn
Lucas Osborn
WMWilliam Joseph Massey
William Joseph Massey
NSNaseer Sangwan
Naseer Sangwan
JBJ. Mark Brown
J. Mark Brown
Obesity has repeatedly been linked to reorganization of the gut microbiome, yet to this point obesity therapeutics have been targeted exclusively toward the human host. Here, we show that gut microbe-targeted inhibition of the trimethylamine N-oxide (TMAO) pathway protects mice against the metabolic disturbances associated with diet-induced obesity (DIO) or leptin deficiency (Lepob/ob). Small molecule inhibition of the gut microbial enzyme choline TMA-lyase (CutC) does not reduce food intake but is instead associated with alterations in the gut microbiome, improvement in glucose tolerance, and enhanced energy expenditure. We also show that gut microbial CutC inhibition is associated with reorganization of host circadian control of both phosphatidylcholine and energy metabolism. This study underscores the relationship between microbe and host metabolism and provides evidence that gut microbe-derived trimethylamine (TMA) is a key regulator of the host circadian clock. This work also demonstrates that gut microbe-targeted enzyme inhibitors have potential as anti-obesity therapeutics.

10 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYi Zhu
Yi Zhu
NLNa Li
Na Li
MHMingyang Huang
Mingyang Huang
MBMason Bartels
Mason Bartels
SDSophie Dogné
Sophie Dogné
PSPhilipp E Scherer
Philipp E Scherer
Plasma hyaluronan (HA) increases systemically in type 2 diabetes (T2D) and the HA synthesis inhibitor, 4-Methylumbelliferone, has been proposed to treat the disease. However, HA is also implicated in normal physiology. Therefore, we generated a Hyaluronan Synthase 2 transgenic mouse line, driven by a tet-response element promoter to understand the role of HA in systemic metabolism. To our surprise, adipocyte-specific overproduction of HA leads to smaller adipocytes and protects mice from high-fat-high-sucrose-diet-induced obesity and glucose intolerance. Adipocytes also have more free glycerol that can be released upon beta3 adrenergic stimulation. Improvements in glucose tolerance were not linked to increased plasma HA. Instead, an HA-driven systemic substrate redistribution and adipose tissue-liver crosstalk contributes to the systemic glucose improvements. In summary, we demonstrate an unexpected improvement in glucose metabolism as a consequence of HA overproduction in adipose tissue, which argues against the use of systemic HA synthesis inhibitors to treat obesity and T2D.

1 September 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CGChristy M. Gliniak
Christy M. Gliniak
JBJ. Mark Brown
J. Mark Brown
NNNoa Noy
Noa Noy
It has long been appreciated that insulin action is closely tied to circadian rhythms. However, the mechanisms that dictate diurnal insulin sensitivity in metabolic tissues are not well understood. Retinol-binding protein 4 (RBP4) has been implicated as a driver of insulin resistance in rodents and humans, and it has become an attractive drug target in type II diabetes. RBP4 is synthesized primarily in the liver where it binds retinol and transports it to tissues throughout the body. The retinol–RBP4 complex (holo-RBP) can be recognized by a cell-surface receptor known as stimulated by retinoic acid 6 (STRA6), which transports retinol into cells. Coupled to retinol transport, holo-RBP can activate STRA6-driven Janus kinase (JAK) signaling and downstream induction of signal transducer and activator of transcription (STAT) target genes. STRA6 signaling in white adipose tissue has been shown to inhibit insulin receptor responses. Here, we examined diurnal rhythmicity of the RBP4/STRA6 signaling axis and investigated whether STRA6 is necessary for diurnal variations in insulin sensitivity. We show that adipose tissue STRA6 undergoes circadian patterning driven in part by the nuclear transcription factor REV-ERBα. Furthermore, STRA6 is necessary for diurnal rhythmicity of insulin action and JAK/STAT signaling in adipose tissue. These findings establish that holo-RBP and its receptor STRA6 are potent regulators of diurnal insulin responses and suggest that the holo-RBP/STRA6 signaling axis may represent a novel therapeutic target in type II diabetes.

19 February 2025 in Nature Aging
Verified
Journal Article
Open access
PDF file
YYYun-Hee Youm
Yun-Hee Youm
CGChristy Gliniak
Christy Gliniak
YZYuan Zhang
Yuan Zhang
TDTamara Dlugos
Tamara Dlugos
PSPhilipp E Scherer
Philipp E Scherer
VDVishwa Deep Dixit
Vishwa Deep Dixit
Age-related thymic involution precedes aging of all other organs in vertebrates and initiates the process of declining T cell diversity, which leads to eventual immune dysfunction. Whether FGF21, a liver-derived pro-longevity hormone that is also produced in thymic stroma, including by adipocytes, controls the mechanism of thymic demise is incompletely understood. Here, we demonstrate that elevation of FGF21 in thymic epithelial cells (TECs) and in adipocytes protects against thymic aging, whereas conditional hepatic overexpression did not impact thymic biology in aged mice. Notably, elevation of thymic FGF21 increased naïve CD8 T cells in aged animals and extended healthspan. Mechanistically, thymic FGF21 overexpression elevated TECs and reduced fibroadipogenic cells. Ablation of β-klotho, the obligatory co-receptor for FGF21 in Foxn1+ TECs, accelerated thymic aging, suggesting regulation of TECs by FGF21 is partially required for thymic lymphopoiesis. These findings establish that paracrine FGF21 improves thymic function and delays immune aging.

3 July 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
QZQingzhang Zhu
Qingzhang Zhu
SCShiuhwei Chen
Shiuhwei Chen
JFJan-Bernd Funcke
Jan-Bernd Funcke
LSLeon G. Straub
Leon G. Straub
QLQian Lin
Qian Lin
PSPhilipp E Scherer
Philipp E Scherer